Dihydralazine is a drug belonging to the class of potassium channel openers, and is used in the treatment of hypertension or high blood pressure. It possess antihypertensive properties to combat the effects of adrenaline in the body. It acts by relaxing the blood vessels and expanding them, which decrease the pressure and eventually lower the blood pressure by allowing smoother flow of blood and oxygen into the heart. This medication is available in the form of a tablet, which removes the potassium from the walls of the arteries to enable proper flow of blood. It is prescribed to patients suffering from heart-related chest pain.
COVID-19 Impact Analysis
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the dihydralazine market.
Top Impacting Factors
Surge in the sedentary lifestyle and rise in prevalence of hypertension lead to the growth of the dihydralazine market.
However, lack of acknowledgement of the disorder in some of the developing countries can pose as a challenge to this market.
Conversely, increase in R&D activities of the medicine department will pave the path for new opportunities in the future for the dihydralazine drugs market.
Market Trends
New Product Launches to Flourish the Market
- In 2019, Mankind Pharma, an Indian pharmaceutical company, launched Zolahart (Azilsartan) to treat commonly related diseases of hypertension.
- In 2021, Quantum Genomics Corp., a biopharmaceutical company, launched Firibastat, a first-in-class drug of the antihypertensive class.
Key Benefits of the Report
- This study presents the analytical depiction of the dihydralazine industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the dihydralazine market share.
- The current market is quantitatively analyzed to highlight the dihydralazine market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis based on competitive intensity and how the competition will take shape in coming years
Questions answered in the dihydralazine report
- Who are the leading players active in the dihydralazine drugs market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "dihydralazine"?
- What is "dihydralazine" market prediction in the future?
Dihydralazine Drugs Market Report Highlights
| Aspects | Details |
 By Condition |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Zafa Pharmaceutical, Xgen, Sterimax, American Regent, Novartis, Akorn, Troika Pharmaceutical |
Loading Table Of Content...
